Physician profile
Alaa Ali
NPI 1841546876
$19,333.21
in general payments reported to CMS, 2019-2025
13 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $5,270 · 2023: $458 · 2024: $318 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,855.00 |
| Food and Beverage | $1,208.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $13,055.49 | 2025 | Yescarta |
| Incyte Corporation | $5,312.50 | 2022-2023 | |
| Legend Biotech USA INC. | $226.62 | 2024-2025 | Carvykti |
| Janssen Biotech, INC. | $180.05 | 2022-2024 | Tecvayli, Darzalex |
| National Marrow Donor Program | $156.36 | 2022 | |
| Sanofi-Aventis U.S. LLC | $123.12 | 2022 | |
| Celgene Corporation | $119.75 | 2022-2025 | Reblozyl, Onureg |
| Novartis Pharmaceuticals Corporation | $61.09 | 2022-2024 | |
| Syndax Pharmaceuticals, INC. | $34.13 | 2025 | |
| Daiichi Sankyo INC. | $24.17 | 2025 | Vanflyta |
| Regeneron Healthcare Solutions, INC. | $22.08 | 2025 | Lynozyfic |
| Beigene USA, INC. | $17.85 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alaa Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.